News
KZR
7.29
0.00%
0.00
Kezar Life Sciences Acquired by Aurinia, Delisted From Nasdaq
TipRanks · 05/11 14:03
Weekly Report: what happened at KZR last week (0504-0508)?
Weekly Report · 05/11 10:09
Weekly Report: what happened at KZR last week (0427-0501)?
Weekly Report · 05/04 10:07
Weekly Report: what happened at KZR last week (0420-0424)?
Weekly Report · 04/27 10:09
Weekly Report: what happened at KZR last week (0413-0417)?
Weekly Report · 04/20 10:06
Weekly Report: what happened at KZR last week (0406-0410)?
Weekly Report · 04/13 10:09
Weekly Report: what happened at KZR last week (0330-0403)?
Weekly Report · 04/06 10:10
Kezar Life Sciences Announces Major Executive Leadership Changes
TipRanks · 04/03 21:27
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aura Biosciences Inc (AURA) and Kezar Life Sciences (KZR)
TipRanks · 03/30 20:50
Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies
TipRanks · 03/30 19:56
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
PR Newswire · 03/30 17:35
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 03/30 17:05
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
TipRanks · 03/30 16:07
Kezar Life Sciences to Be Acquired by Aurinia
TipRanks · 03/30 14:26
Aurinia Pharmaceuticals acquiring Kezar Life Sciences
Seeking Alpha · 03/30 14:06
Aurinia Pharma To Acquire Kezar Life Sciences For $6.96 In Cash Per Share And CVR Deal; Stock Up
NASDAQ · 03/30 13:42
Aurinia to Acquire Kezar Life Sciences
Dow Jones · 03/30 13:02
Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
TipRanks · 03/30 12:27
Aurinia Pharmaceuticals Signs Agreement To Acquire Kezar Life Sciences For $6.955/Share In Cash
Benzinga · 03/30 12:04
Press Release: Aurinia Pharmaceuticals to Acquire -2-
Dow Jones · 03/30 12:01
More
Webull provides a variety of real-time KZR stock news. You can receive the latest news about Kezar Life Sciences through multiple platforms. This information may help you make smarter investment decisions.
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.